Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BioXcel Gets First Approval With Igalmi For Neuropsychiatric Agitation

Apr 06 2022

• By Joseph Haas

Anxiety — BioXcel's new sublingual film can address anxiety in psychiatric patients • Source: Alamy

Related Content

Alexza's Adasuve crosses US finish line, but distribution limited

Dec 22 2012

BioXcel Turns To Commercialization With Positive Phase III Data In Agitation

Jul 20 2020

Alkermes Expects Gradual Ramp-Up For Lybalvi Launch

Jun 01 2021

BioXcel's BXCL501 Data In Dementia Patients Reinforce Its Efficacy In Agitation

Jan 05 2021

New Products Shake Up Overlooked Bipolar Disorder Market

Mar 08 2022

Related Companies

BioXcel Therapeutics, Inc.

Alexza Pharmaceuticals, Inc.

Alkermes plc

Intra-Cellular Therapies, Inc.

Additional Topics

Approvals Business Strategies Drug Delivery Technology Commercial Neurology BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.